NASDAQ:CRMD
CorMedix (CRMD) Q3 2025: Net Income Hits $108.6M, FY25 Guidance Raised to $390–$410M — Nov 12, 2025
CorMedix Inc. reported a profitable third quarter and lifted full‑year guidance today as momentum in DefenCath and contributions from the Melinta portfolio accelerated growth. TradingView
Company hubNASDAQ:CRMD
CRMD (CRMD) Stock News & Analysis
Follow the latest CRMD (CRMD) company news, earnings coverage and investor analysis from TechStock².
Save this hub to your TS2 Signalbook account.
- Latest update
- Articles in this hub
- 1
- Last 30 days
- 0
What investors are watching
- Earnings, guidance and financial performance
- Valuation, trading activity and market sentiment
- Strategy, catalysts and company-specific risks
All coverage